Houston-based Well Power is targeting the oil and gas industry with a particular focus on commercializing a patented solution to convert flared, shut-in and stranded gas into clean power and engineered fuels. Using this mobile, high-yield technology licensed from ME Resources Corp. (“MEC”), Well Power aims to reduce waste emission and capitalize on this niche market of the oil and gas industry.

Each year, billions of cubic meters of natural gas are flared at oil production sites all over the world. According to the World Bank Group, gas flaring not only wastes a valuable energy resource, it also contributes to climate change by releasing more than 300 million tons of CO2 into the atmosphere.

In April, The World Bank announced that chief executives from major oil companies, including Royal Dutch Shell (NYSE:RDS-A, NYSE:RDS-B) and Statoil CEO (NYSE:STO), were convening with senior government officials from several oil-producing countries to commit to ending routine gas flaring. Already endorsed by nine countries, 10 oil companies and a handful of development institutions, United Nations Secretary-General Ban Ki-moon and World Bank Group President Jim Yong Kim concurrently launched the “Zero Routine Flaring by 2030” initiative to end routine gas flaring at oil production sites by the year 2030.

“Gas flaring is a visual reminder that we are wastefully sending CO2 into the atmosphere,” Jim Yong Kim stated in an earlier news release. “We can do something about this. Together we can take concrete action to end flaring and to use this valuable natural resource to light the darkness for those without electricity.”

Well Power is gearing up to participate in this broader movement through the commercialization of the licensed Micro-Refinery Unit (MRU), which processes raw natural gas into green fuel (such as diluents, drop-in diesel and pipeline quality synthetic crude) and clean power. MEC’s solution simultaneously reduces CO2 emissions while creating revenue streams with minimal capital expenditure.

Well Power has secured the licensing rights to Texas with the first right of refusal on the other U.S. states, such as North Dakota, where gas flaring is a significant and concern. The company plans to be able to provide its technology with full-service engineering, design, construction, modular fabrication, maintenance and construction management services to clients in the upstream areas of exploration and production.

In addition, Well Power will offer consulting services, process assessments, facility appraisals, feasibility studies, technology evaluations, project finance structuring and support, and multi-client subscription services.

Leveraging the potential of the MRUs, Well Power is aligned with the Zero Routine Flaring by 2030 initiative and offers the opportunity to create value from a wasted resource while enabling wider access to energy, improved environmental conditions, and economic development for local populations.

For more information, visit www.wellpowerinc.com

Let us hear your thoughts: Well Power Inc. Message Board

GrowBLOX Sciences has entered into a Note Purchase Agreement with Pacific Leaf Ventures, LP in which Pacific Leaf has agreed to make an installment loan to GrowBLOX of up to $1.75 million. According to an SEC filing, the financing provides the funding for GrowBLOX subsidiary GB Sciences Nevada, LLC to acquire and install an operating facility, equipment, and other tangible assets for the cultivation of cannabis and the extraction of oils and other constituents present in cannabis, in adherence to Nevada legal requirements.

GBS Nevada holds a provisional certificate from the Division of Public & Behavioral Health of the Nevada Department of Health and Human Services to operate an establishment to cultivate medical cannabis in Clark County Nevada. The certificate is considered provisional until the establishment is in compliance with applicable local government requirements and has received a state business operating license.

In a related development, GrowBLOX also entered into an exclusive perpetual license agreement to make use of Pacific Leaf’s intellectual property (IP) for the cultivation of cannabis and extraction of oils and other strains of cannabis that it has developed or acquired for the sole use of GBS Nevada in its operations within the state of Nevada. In consideration for the license, GrowBLOX has agreed to pay Pacific Leaf a 14 percent royalty for a period of five years, and a 7 percent royalty each year for five years thereafter.

As part of the Pacific Leaf license, GrowBLOX was also granted the exclusive perpetual right in Nevada to use certain proprietary techniques developed by Pacific Leaf for the extraction of oils from the product grown in the Nevada facility, using the extraction equipment financed by the proceeds of the Pacific Leaf loan. In connection therewith, GrowBLOX agreed to pay a royalty of $2 per extracted gram for a period of five years.

GrowBLOX said it believes that the rights to Pacific Leaf’s IP will give GBS Nevada a “significant competitive advantage in the Nevada cannabis market.” This advantage is complementary to GrowBLOX’s broader business strategy to integrate state-of-the-art technologies in plant biology, cultivation, and post-production processes to optimize safe, consistent medical cannabis.

For more information, visit www.gbsciences.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

Earlier this morning Net Element announced that CEO Oleg Firer will be participating in a discussion to be held June 19th 2015 at the St. Petersburg International Economic Forum.

Fellow panelists will include senior executives from Citi, Accenture, Telenor Group, Visa Inc., IBM and Sberbank. The discussion is entitled “THE FUTURE OF THE ELECTRONIC WALLET AND THE MODERNIZATION OF GLOBAL PAYMENT PLATFORMS.”

The event’s website states, “SPIEF gathers the leading decision-makers of the emerging economic powers to identify and deliberate the key challenges facing Russia, emerging markets, and the world at large, while engaging communities to find common purpose and establish frameworks to forge solutions which will drive the growth and stability agenda.”

For more information about the discussion and SPIEF, visit http://www.forumspb.com/en/2015/sections/50/materials/260/sessions/1121

Rosetta Genomics, Ltd. (NASDAQ: ROSG) leverages an integrative research platform to develop and commercialize a full range of microRNA-based molecular diagnostics and address critical needs in cancer and other disease areas. Building on its proprietary platform technologies and a strong IP portfolio, the company is working to solve unmet medical needs and improve the lives of patients through a proven combination of diagnostic expertise and therapeutic innovations.

The company’s current product pipeline includes an assortment of unique diagnostic tests for a collection of medical conditions – including thyroid neoplasia, heart failure, kidney rejection and Alzheimer’s disease. In recent months, Rosetta has worked to build on this pipeline and expand its presence in the industry, most notably through the acquisition of PersonalizeDx in April. PersonalizeDx is a rapidly growing molecular diagnostics and services company serving community-based pathologists, urologists, oncologists and other reference laboratories across the United States.

“The acquisition of PersonalizeDx will have wide-ranging, positive financial, commercial, operational and pipeline impact on Rosetta Genomics, and brings with it exceptional talent to complement the industry-leading team at Rosetta Genomics,” stated Kenneth A. Berlin, president and chief executive officer of Rosetta, in a recent news release. “In joining forces with PersonalizeDx, Rosetta Genomics will gain critically important commercial and revenue scale in the marketplace for oncology diagnostics.”

In May, Rosetta built on the momentum gained from its acquisition by releasing OncoGxOne™, the company’s next-generation sequencing panel that detects a vast number of genetic alterations implicated in cancer to provide clear, concise and actionable clinical recommendations from a single, comprehensive test. Moving forward, OncoGxOne™ will compete with currently available genomic profiling offerings through next-generation sequencing platforms that can identify potentially actionable cancer-driving mutations, which can be targeted by specific therapies.

“We look forward to a successful commercial launch for OncoGxOne™ with our recently-expanded sales force and expect that over time it will become an important contributor to our revenues,” concluded Berlin.

Rosetta’s recent efforts have strategically positioned the company to realize significant increases in revenue in the coming years. Based on PersonalizeDx’s 2014 revenue, which was $6.9 million, the company has modified its financial model, leading to forecast revenue of $18.5 million in 2016. For prospective investors, this potential growth could provide the opportunity for significant returns in the future.

For more information, visit www.rosettagenomics.com

Soul and Vibe Interactive, Inc. (OTCQB: SOUL) is an innovative video and computer games company focused on developing and publishing standout games. The company specializes in the creation of original intellectual property (IP) and has extensive experience licensing world-renowned brands from influential companies, including General Mills (GIS) and Deere & Company (DE). SOUL’s proven business model centers on multi-platform support, allowing the company to market licensed-brand and original IP-based games that can be played on consoles, mobile devices, and personal computers.

According to a report by PricewaterhouseCoopers, consumer spending on console, mobile and personal computer gaming software topped $56 billion in 2010, and gaming industry revenue is projected to reach $82 billion this year. Despite the overall maturity of the gaming industry’s distribution and marketing efforts in retail settings, digital distribution is forcing the market to evolve, putting SOUL in a strong position to capitalize moving forward. Through partnerships with some of the world’s most technically sophisticated software developers, the company is in a strong position to increase market share through the creation and licensing of engaging, highly accessible and affordable games and entertainment experiences.

In April, SOUL announced the latest addition to its IP portfolio, SirVival, a fast-paced adventure game. In keeping with the company’s multi-platform strategy, the game will be released on Apple’s App Store, Google Play, Amazon, Microsoft Store Marketplace and Facebook. Earlier this month, the company continued efforts to grow brand recognition and created an additional channel to realize sustainable returns through the announcement of Soul and Vibe Music, a publishing label through which music singles and soundtracks will be released. Soul and Vibe Music is expected to be released via digital download on iTunes, Spotify, Google Play, Amazon, Rdio, Deezer, Tidal, YouTube Music Key, Beats/MediaNet and more.

“Soul and Vibe is a name that lends itself to a wide variety of entertainment mediums,” Peter Anthony Chiodo, president and chief executive officer of SOUL, stated in a news release. “While we work as a team to expand our portfolio of published content, it makes sense for us to separately leverage select elements of that content in unique ways so it can potentially expand monetization opportunities for the company.”

Moving forward, SOUL will look to continue expanding its presence in the gaming industry through strategic licensing agreements and the creation and utilization of IP. For prospective investors, the company’s continued progress toward the launch of SirVival makes it an intriguing option to consider in the months to come.

For more information, visit www.soulandvibe.com

Ohr Pharmaceutical is an ophthalmology research and development company. Its lead product, Squalamine, is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored phase II clinical trials for various back-of-the-eye diseases, including wet age-related macular degeneration (wet AMD), retinal vein occlusion, diabetic macular edema and proliferative diabetic retinopathy. The company’s second product, OHR/AVR118, is designed to treat cancer cachexia, which is commonly known as wasting syndrome. Through these two candidates, Ohr’s product pipeline offers a new ray of hope to patients suffering from these devastating diseases.

Unlike current wet AMD treatment options, which are administered via injection directly into the eye, Ohr’s innovative Squalamine formulation is designed for self-administration, eliminating the need for painful intravitreal injections and providing a significant cost advantage, as compared to the current standards of care. According to a report by the National Eye Institute, wet AMD is a common eye condition and a leading cause of vision loss among people aged 50 and older, affecting over 1.75 million patients in the United States alone. Through the development of Squalamine, Ohr could effectively revolutionize the standard treatment option for this condition, creating a formidable platform to realize significant growth in the ophthalmology market.

In addition to Squalamine, Ohr is addressing a vastly underserved market through the continued development of OHR/AVR118 for the treatment of cancer cachexia. Cancer cachexia is a severe wasting disorder characterized by a significant loss of appetite, weight loss, fatigue, weakness and muscle atrophy. Currently, there is no FDA approved drug for the treatment of this debilitating condition, providing Ohr with another opportunity to realize sustainable increases in shareholder returns.

With a product pipeline including two unique drug candidates in four distinctive indications currently undergoing phase II clinical trials, Ohr is continuing to set the stage for rapid increases in market share in the years to come. For prospective investors, this progress makes Ohr an intriguing option moving forward.

For more information, visit www.ohrpharmaceutical.com

Vycor Medical, Inc. (OTCQB: VYCO) is changing and improving lives every day by providing the medical community with innovative and superior surgical and therapeutic tools, including a growing portfolio of FDA-cleared medical solutions. The company currently operates two unique but complementary business units, Vycor Medical and NovaVision, which adopt a minimally or non-invasive approach to a collection of underserved medical applications.

Through its Vycor Medical unit, the company designs, develops and markets the ViewSite Brain Access System (VBAS), a proprietary suite of clear cylindrical disposable devices used to gain access to specific neurological sites, such as tumors within the brain. Vycor’s innovative medical instruments are designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community.

In recent months, the company has made significant headway toward expanding VBAS’s presence within the medical industry, increasing the number of U.S. hospitals for which the system is approved to more than 190 during the first quarter of 2015. In large part, this growth has come as a result of increasingly prevalent scientific data on the system. According to a recently released study on VBAS published by surgeons from Sapporo Medical University in Japan, the suite is believed to provide a safer, more reliable, and less invasive method for the treatment of deep-seated brain tumors.

“We continue to make good progress with our VBAS product and the new studies we are anticipating this year together with the launch of additional products makes me confident this will translate into increased VBAS penetration and greater market acceptance during the course of this year,” stated Peter Zachariou, chief executive officer of Vycor, in a recent news release.

Through its NovaVision unit, Vycor targets a substantial and largely unaddressed market of people who have lost their sight as a result of stroke or traumatic brain injury. The company’s family of therapies, which are clinically supported by decades of scientific research, both restore and help to compensate for lost vision.

NovaVision’s unique product offerings have gained significant industry traction in recent months. Late in 2014, the company received receipt of approval from HealthSouth to offer the NovaVision VIDIT diagnostic device, and, earlier this month, Vycor continued on this success by partnering with HealthSouth for a second time to make available its NeuroEyeCoach Professional Center therapy program. These two agreements provide the company with access to a potentially massive source of patients, as HealthSouth is one of the largest providers of post-acute healthcare services in the country.

“NovaVision is now positioned, for the first time, with the suite of therapies and product offerings to deliver on our strategic vision: to provide a clinically supported, affordable and scalable visual therapy solution offering broad benefits to those suffering from visual impairment following neurological damage,” continued Zachariou.

Moving forward, Vycor is in an increasingly strong position to realize enhanced returns. Despite a slim decrease in reported year-over-year revenue for the first quarter of 2015, the company’s recently announced agreements with HealthSouth, as well as expanding product approval rates for the VBAS, make Vycor an intriguing option for prospective investors in the months to come.

For more information, visit www.vycormedical.com

Pure Hospitality Solutions, in an effort to continue building shareholder confidence, recently released a collection of site design snapshots for its upcoming Central American-Caribbean online travel hub, Oveedia.

“[W]e are currently at a stage where testing will soon begin and an early launch is likely,” Melvin Pereira, president and chief executive officer of Pure, stated in a news release. “Our programmers are working tirelessly to ensure Oveedia’s launch is not only accelerated, but that an ultra-friendly user experience is achieved by front-end consumers.”

With the snapshots, Pure is providing shareholders with a glimpse into the style, functionality and design of the Oveedia platform. Along with two unique desktop versions of its design, the preview also includes both tablet and mobile design snapshots, highlighting the quantifiable progress of Pure in recent months.

“We are exploring two differently designed, ultra-responsive versions, all shown as the platform will appear on a desktop, smartphone or tablet,” continued Pereira. “We are on our way to having one of the most incredible assets in the history of our organization.”

In May, Pure took a significant step toward increasing the potential value of Oveedia by becoming a member of the Sabre Travel Network. Through this agreement, the company gained access to a $7 billion booking network, including more than 125,000 hotels, 400 airlines, 16 cruise lines and 25 car rental selections. In addition to its partnership with Sabre, Pure has also made major strides toward a sustainable presence in the growing Central American-Caribbean travel industry through the continued expansion of its standalone travel network. Last week, the company added Jaco Tour Company to the fold, and expansion to approximately 300 hotels and travel-related businesses is expected by the end of the year.

According to a report by Amadeus, the online travel agency segment in the Latin American market is expected to account for $98.5 billion in 2016, providing Pure with the opportunity to realize rapid increases in market share following Oveedia’s initial release. Integration with the Sabre Travel Network, as well as continued expansion of Pure’s standalone region-specific travel network, should make Oveedia a strong acquisition target for larger, globally dominant OTAs – including Expedia and Priceline – in the years to come. For prospective shareholders, the impending launch of Oveedia makes Pure an intriguing investment opportunity moving forward.

For more information on Pure Hospitality Solutions, visit www.purenow.solutions

Let us hear your thoughts: Oriens Travel and Hotel Management Corp. Message Board

Baltimore, Maryland-based View Systems provides state-of-the-art security technology products for the growing $100 billion a year security industry. The company’s solutions are applicable for a wide range of entities in need of security solutions, including correctional institutions, government agencies, schools, courthouses, event and sports venues, the military and commercial businesses.

ViewScan, the company’s flagship product, is an advanced walk-through Concealed Weapons Detection System (CWD) that utilizes highly sensitive, completely passive sensor technology that drastically simplifies the process of discriminating suspicious items from harmless ones. The technology accurately detects the location and number of threat objects such as knives, guns and razor blades while ignoring personal artifacts like coins, keys and belt buckles.

While highly accurate, the system does not emit electro-magnetic fields, radiation, millimeter waves or X-rays, which means it’s safe for pacemakers, implants and pregnant women. In addition, ViewScan has been designated by the U.S Department of Homeland Security as a Qualified Anti-Terrorism Technology (QATT).

Due to a high demand from the correctional industry, View Systems added the LAW Handheld Metal Detector to its Weapon Detection Devices product line. The company’s NEW Law is a high-sensitivity metal detector that features rapid speed and high definition technology that makes it highly complementary to the ViewScan.

View Systems’ first response remote video transmission system is utilized in areas where hazardous materials have been exposed. The solution is small enough to be worn on a belt, helmet or vest, and it transmits conventional video or infrared imagery to the command post, making it ideal for law enforcement SWAT teams, Fire Rescue units and HAZMAT team operations.

The company is constantly conducting research and development to ensure its technologies evolve with the changing security environment. Leading this charge is a senior management team is comprised of successful businessmen with decades of business and professional experience in the security industry.

For more information, visit www.viewsystems.com

Let us hear your thoughts: View Systems, Inc. Message Board

Milestone Scientific, Inc. (NYSE MKT: MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Since 1995, the company’s commitment to advancing the science of computer-controlled drug delivery technologies has helped it earn global distinction as an industry leader in the fields of medicine and dentistry. Milestone’s patented CompuFlo® system and DPS Dynamic Pressure Sensing® technology are revolutionary tools that enable practitioners to accomplish a collection of tasks that exceed the capabilities of the 150 year-old manual syringe.

The CompuFlo® system provides a safer, painless delivery alternative for all types of subcutaneous injections in the medical practice. Utilizing Milestone’s proprietary pressure sensing technology, the system offers safe, effective feedback to assist healthcare providers in identifying a specific anatomic location. In addition to more accurate injections, the platform is capable of documenting injection events to provide more reliable recordkeeping for both patients and healthcare providers.

In recent months, Milestone, through its Epidural & IA subsidiary, has turned its attention towards a clinical trial to verify the placement of the epidural needle tip in the lumbar epidural space. Since receiving FDA approval in March, the company has opened enrollment for clinical testing, aiming to enroll up to 400 patients in the trial at four sites throughout the United States.

“A major focus of the Company in 2015 is commercializing the first medical applications of our technology platform, including those licensed by our Epidural & IA Subsidiary,” stated Leonard Osser, Chief Executive Officer of Milestone. “Our Epidural & IA Subsidiary has been in negotiations with distributors in a number of countries… [and] recently signed its first distribution agreement with TRIMED SP.z.o.o., one of the largest distributors of diagnostic equipment in Poland.”

In the first quarter of 2015, Milestone made took major steps towards realizing sustainable growth by signing a letter of intent with MILA International for marketing, distribution and commercialization of an anesthetic delivery instrument for maxillary nerve block procedures in horses. Through this agreement, the company will gain access to the $24 billion global animal health industry, providing an additional platform for continued expansion.

“Our strategy is to collaborate on the development, commercialization and distribution of an anesthetic delivery instrument… [for which] MILA will be responsible for marketing and distribution and Milestone will manufacture product,” continued Osser.

For prospective investors, the company’s continued dedication to innovation and an increasingly broad collection of target markets provide the opportunity to realize sustainable returns in the future.

For more information, visit www.milesci.com